Order Article Reprints

Sahnane N, Carnevali I, Formenti G, Casarin J, Facchi S, Bombelli R, Di Lauro E, Memoli D, Salvati A, Rizzo F, et al. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor. International Journal of Molecular Sciences. 2020; 21(24):9708. https://doi.org/10.3390/ijms21249708

Sahnane, Nora, Ileana Carnevali, Giorgio Formenti, Jvan Casarin, Sofia Facchi, Raffaella Bombelli, Eleonora Di Lauro, Domenico Memoli, Annamaria Salvati, Francesca Rizzo, and et al. 2020. "BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor" International Journal of Molecular Sciences 21, no. 24: 9708. https://doi.org/10.3390/ijms21249708

Sahnane, N., Carnevali, I., Formenti, G., Casarin, J., Facchi, S., Bombelli, R., Di Lauro, E., Memoli, D., Salvati, A., Rizzo, F., Sessa, F., & Tibiletti, M. G. (2020). BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor. International Journal of Molecular Sciences, 21(24), 9708. https://doi.org/10.3390/ijms21249708